BACKGROUND: Kidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is unclear how the willingness to be listed for and accept such kidneys affects waitlist and transplant outcomes. METHODS: In a single-center retrospective analysis, HCV+ transplant candidates (N = 169) listed from March 2004 to February 2015 were evaluated. All RNA+ candidates were offered the option to be listed for HCV+ donors. RNA- candidates were listed only for HCV- donors. RESULTS: Fifty-seven patients (51% of all RNA+ transplant candidates) willing to accept HCV+ donors were listed for both HCV+ and HCV- donor kidneys. During 6-year follow up, 43 (75%) of 57 patients accepting HCV+ versus 19 (35%) of 55 patients not accepting HCV+ received a deceased donor kidney transplant (P < 0.0001). Multivariable analysis demonstrated that willingness to be listed for and accept HCV+ kidneys was associated with receiving deceased donor kidney transplant (P = 0.0016). Fewer patients accepting HCV+ donors (7 [12%] vs 16 [29%]) were removed from the list due to death or deteriorated medical condition (P = 0.0117). Posttransplant patient and graft survival rates were not significantly different. Overall patient survival since the listing (combined waitlist and posttransplant survival) was similar among the groups. CONCLUSIONS: HCV RNA+ candidates had better access to transplantation and similar overall survival before the era of widespread use of direct-acting anti-HCV agents.
BACKGROUND: Kidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is unclear how the willingness to be listed for and accept such kidneys affects waitlist and transplant outcomes. METHODS: In a single-center retrospective analysis, HCV+ transplant candidates (N = 169) listed from March 2004 to February 2015 were evaluated. All RNA+ candidates were offered the option to be listed for HCV+ donors. RNA- candidates were listed only for HCV- donors. RESULTS: Fifty-seven patients (51% of all RNA+ transplant candidates) willing to accept HCV+ donors were listed for both HCV+ and HCV- donor kidneys. During 6-year follow up, 43 (75%) of 57 patients accepting HCV+ versus 19 (35%) of 55 patients not accepting HCV+ received a deceased donor kidney transplant (P < 0.0001). Multivariable analysis demonstrated that willingness to be listed for and accept HCV+ kidneys was associated with receiving deceased donor kidney transplant (P = 0.0016). Fewer patients accepting HCV+ donors (7 [12%] vs 16 [29%]) were removed from the list due to death or deteriorated medical condition (P = 0.0117). Posttransplant patient and graft survival rates were not significantly different. Overall patient survival since the listing (combined waitlist and posttransplant survival) was similar among the groups. CONCLUSIONS: HCV RNA+ candidates had better access to transplantation and similar overall survival before the era of widespread use of direct-acting anti-HCV agents.
Authors: J M Morales; J M Campistol; B Domínguez-Gil; A Andrés; N Esforzado; F Oppenheimer; G Castellano; A Fuertes; M Bruguera; M Praga Journal: Am J Transplant Date: 2010-11 Impact factor: 8.086
Authors: Joseph R Scalea; Rolf N Barth; Raghava Munivenkatappa; Benjamin Philosophe; Matthew Cooper; Victoria Whitlow; John C LaMattina Journal: Transplantation Date: 2015-06 Impact factor: 4.939
Authors: Kevin C Abbott; Krista L Lentine; Jay R Bucci; Lawrence Y Agodoa; Thomas G Peters; Mark A Schnitzler Journal: Am J Transplant Date: 2004-12 Impact factor: 8.086
Authors: Panduranga S Rao; Douglas E Schaubel; Mary K Guidinger; Kenneth A Andreoni; Robert A Wolfe; Robert M Merion; Friedrich K Port; Randall S Sung Journal: Transplantation Date: 2009-07-27 Impact factor: 4.939
Authors: Craig E Gordon; Ethan M Balk; Bryan N Becker; Peter A Crooks; Bertrand L Jaber; Cynda A Johnson; Maureen A Michael; Brian J G Pereira; Katrin Uhlig; Adeera Levin Journal: Am J Kidney Dis Date: 2008-11 Impact factor: 8.860
Authors: Mary G Bowring; Lauren M Kucirka; Allan B Massie; Tanveen Ishaque; Sunjae Bae; Ashton A Shaffer; Jacqueline Garonzik Wang; Mark Sulkowski; Niraj Desai; Dorry L Segev; Christine M Durand Journal: Transplantation Date: 2018-12 Impact factor: 4.939